Edition:
India

PhaseRx Inc (PZRX.OQ)

PZRX.OQ on NASDAQ Stock Exchange Capital Market

0.66USD
17 Nov 2017
Change (% chg)

$0.02 (+3.12%)
Prev Close
$0.64
Open
$0.67
Day's High
$0.67
Day's Low
$0.64
Volume
694
Avg. Vol
58,505
52-wk High
$3.30
52-wk Low
$0.55

Summary

Name Age Since Current Position

Steven Gillis

63 2008 Independent Chairman of the Board

Robert Overell

61 2017 President, Chief Executive Officer, Principal Accounting Officer, Secretary, Director

Sean Monahan

2015 Vice President - Chemistry

Mary Prieve

2015 Vice President - Biology

Gordon Brandt

57 2016 Chief Medical Officer

James Watson

2015 Head of Corporate Development

Paul Johnson

73 2015 Director

Brian Atwood

64 2008 Independent Director

Michelle Griffin

51 2016 Independent Director

Peggy Phillips

63 2016 Independent Director

John Schmidt

66 2010 Independent Director

Erin Cox

2015 IR Contact Officer

Biographies

Name Description

Steven Gillis

Dr. Steven H. Gillis, Ph.D., is Independent Chairman of the Board of the Company. Dr. Gillis, has served as a chairman of our board of directors since 2008. Since 2005, Dr. Gillis has been a managing director at ARCH Venture Fund, a venture capital firm. From 1994 to 2005, Dr. Gillis served as chief executive officer and chairman of the board of directors of Corixa Corporation, which he co-founded in October 1994. Previously, Dr. Gillis served as a director, head of research and development, chief scientific officer and acting chief executive officer of Immunex Corporation, which he co-founded, from 1981 until his departure in 1994. Dr. Gillis led the acquisition of Trubion Pharmaceuticals, Inc. by Emergent BioSolutions in the fall of 2010. Dr. Gillis currently serves as a director of Shire plc (NASDAQ: SHPG), Accelerator Corporation, Oncofactor Corp., VBI Vaccines Inc. (NASDAQ: VBIV), Pulmatrix, Inc. (NASDAQ: PULM) and serves as director and chairman of VentiRX Pharmaceuticals, Inc., Theraclone Sciences, Inc. and Lycera Corp. Dr. Gillis previously served as a director at bluebird bio, Inc. from 2011 to 2015. Dr. Gillis received his B.A. in biology and English from Williams College and his Ph.D. in biological science from Dartmouth College.

Robert Overell

Dr. Robert W. Overell, Ph.D., is re designated as President, Chief Executive Officer, Principal Accounting Officer, Secretary, Director of the Company. Dr. Overell has served as the president and member of the board of directors since 2006 and chief executive officer since 2009. Prior to our first institutional financing in 2008, Dr. Overell was president of Foundation BioVentures LLC, which provided company formation and consulting services to startup companies, including us. Prior to that, Dr. Overell was a consultant, venture partner, then general partner, with Frazier Healthcare Ventures from 1996 to 2005, where he participated in raising over $600 million of venture capital and invested over $60 million in early-stage biotechnology companies. Dr. Overell has served on numerous corporate boards, including Array Biopharma Inc. (NASDAQ: ARRY) from 1998 to 2002, XenoPort, Inc. (NASDAQ: XNPT), which he co-founded in 1999, from 1999 to 2005, and Chimerix, Inc. (NASDAQ: CMRX) from 2004 to 2005. Dr. Overell helped found Immunex Corporation’s gene therapy spinout, Targeted Genetics Corp., where he led product development and gene delivery programs from 1992 to 1996. Dr. Overell joined Immunex Corporation in 1984, where led programs in cell and molecular biology. He also led development of the first human immunodeficiency virus gene therapy trial in the world, which was approved by the Recombinant DNA Advisory Committee of the National Institutes of Health and the FDA in 1991. Dr. Overell obtained a B.Sc. in biological sciences from the University of Newcastle-upon-Tyne and a Ph.D. in biochemistry from the Institute of Cancer Research, University of London, United Kingdom.

Sean Monahan

Dr. Sean Monahan, Ph.D., is Vice President - Chemistry of the Company. Dr. Monahan, joined PhaseRx as the director of chemistry in July, 2009, bringing more than ten years of experience in the area of nucleic acid delivery technologies. From 1998 to 2011, Dr. Monahan served in various capacities with Roche / Mirus Bio Corporation (senior scientist I – III). In this capacity, Dr. Monahan was involved in the development of both lipid and polymeric systems for the delivery of drugs and nucleic acids in both the research and product areas. From 1996 to 1998, Dr. Monahan worked in medicinal chemistry, new lead discovery, at Berlex Biosciences, the U.S. Research and Development Center for Schering AG in Germany. Dr. Monahan received a B.A. in chemistry from the University of Colorado, Boulder, and a Ph.D. in organic chemistry from the University of Wisconsin, Madison. Dr. Monahan has authored numerous papers and patents in the areas of drug and nucleic acid delivery.

Mary Prieve

Dr. Mary G. Prieve, Ph.D., is Vice President - Biology of the Company. Dr. Prieve joined PhaseRx in February 2008 as director of biology. Dr. Prieve leads the biology and formulation teams to develop polymer based nanoparticles for the delivery of siRNA and mRNA to target tissues of interest. Dr. Prieve has over a decade of experience in biochemical, cell-based, and molecular assay development as well as animal pharmacology. Therapeutic applications have focused in the areas of cancer and orphan liver disease at PhaseRx. From 2004 – 2007 she was a senior research scientist at Nastech Pharmaceutical Company Inc. In this role she led the in vivo pharmacology team which centered on peptide and lipid based delivery of siRNA for the treatment of inflammatory, infectious (influenza), and metabolic diseases. From 2003 to 2004, Dr. Prieve was a visiting assistant professor at Smith College and a lecturer in cell and general biology courses at University of Washington and Seattle University. From 1999 – 2003 she did her post-doctoral training at the University of Washington in Dr. Randall Moon’s Laboratory in the area of Wnt signal transduction. She received a B.S. degree in chemistry from University of California, Santa Barbara and a Ph.D. in biological sciences from University of California, Irvine.

Gordon Brandt

Mr. Gordon Brandt, M.D., is Chief Medical Officer of the Company. Dr. Brandt previously served as PhaseRx's chief clinical advisor, and has been working with the company for five years. Prior to this, he served as president and executive vice president of clinical research and medical affairs for Nastech Pharmaceutical Company Inc. (which became MDRNA Inc.), where he worked to develop nucleic acid therapeutics. Previously, Dr. Brandt worked at Sonus Pharmaceuticals, Inc., a developer of oncology drugs, where he held the positions of vice president, clinical and regulatory affairs, and director of medical affairs. Dr. Brandt graduated from Yale University with a B.S. degree in engineering science, received an M.D. from the University of California, San Francisco, and completed his residency training in internal medicine at Kaiser Hospital in San Francisco. He has worked in the medical device, biologic, and drug fields for more than 30 years, and has successfully led both US and EU drug approval programs.

James Watson

Mr. James D. Watson, MBA, is Head of Corporate Development of the Company. Mr. Watson most recently served as chief business officer at Alvine Pharmaceuticals, Inc. from 2011 to 2016, and, prior to that, was a managing director and head of private equity at Burrill & Company and chief executive officer of Burrill & Company’s merchant banking group.

Paul Johnson

Dr. Paul H. Johnson, Ph.D., is Director of the Company. Dr. Johnson, has served as a member of our board of directors since 2007. From 2007 to 2015, Dr. Johnson served as our chief scientific officer. From 2003 to 2007, Dr. Johnson was senior vice president, research and development, and chief scientific officer of Nastech Pharmaceutical Company, Inc. From 2000 to 2003, Dr. Johnson served as vice president, research and development, and chief scientific officer of EpiGenx Pharmaceuticals, Inc. Since 2014, Dr. Johnson has been executive vice president and chief scientific officer of Next Frontier Biosciences. Dr. Johnson received a B.S. in molecular biology from the State University of New York, Buffalo and a Ph.D. in biochemistry from Roswell Park Cancer Institute (SUNY).

Brian Atwood

Mr. Brian G. Atwood is Independent Director of the Company. Mr. Atwood has served as a member of our board of directors since 2008. Since 1999, Mr. Atwood has served as managing director of Versant Ventures, a healthcare-focused venture capital firm he co-founded. Prior to co-founding Versant Ventures, Mr. Atwood spent four years at Brentwood Associates, a venture capital firm, where, as a general partner, he led investments in biotechnology, pharmaceuticals and bioinformatics. Mr. Atwood founded Glycomed, Inc. and served as its president and chief executive officer from 1993 to 1995. Mr. Atwood currently serves on the board of directors of Clovis Oncology, Inc. (NASDAQ: CLVS), Atreca, Inc., Five Prime Therapeutics, Inc. (NASDAQ: FPRX), Immune Design Corp. (NASDAQ: IMDZ), OpGen, Inc., Spark Diagnostics, Inc., and Veracyte, Inc. (NASDAQ: VCYT). Mr. Atwood was previously a member of the board of directors of Helicos Biosciences (NASDAQ: HLCS), and Pharmion Corporation, and Trius Therapeutics, Inc. (NASDAQ: TSRX) acquired in 2013, and Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) acquired in 2014. Mr. Atwood received a B.S. in biological sciences from the University of California, Irvine, an M.S. in ecology from the University of California, Davis, and an MBA from Harvard Business School.

Michelle Griffin

Ms. Michelle Renee Griffin is Independent Director of the Company. Ms. Griffin, has served as a member of our board of directors since February 2016. Ms. Griffin currently provides consulting services to biotechnology companies and boards of directors through her firm, Pacific Biotechnology Consulting Group. Ms. Griffin served as a member of the board of directors for Polynoma LLC from 2012 to 2014. Ms. Griffin served as executive vice president, operations, and as chief financial officer at OncoGenex Pharmaceuticals Inc. from January 2011 to March 2013. Prior to that, Ms. Griffin served as a member of the board of directors of OncoGenex Pharmaceuticals Inc. from May 2004 to January 2011. Ms. Griffin served as acting chief executive, senior vice president and chief operating officer at Trubion Pharmaceuticals, Inc., a biopharmaceutical company, from February 2006 until its acquisition in October 2010 by Emergent BioSolutions, Inc. From August 2005 to January 2006, Ms. Griffin served as senior vice president and chief financial officer of Dendreon Corporation, a biotechnology company. From March 1995 to July 2005, she was employed by Corixa Corporation, a biotechnology company, and served as its chief financial officer from 1997 until 2005 when Corixa Corporation was acquired by GlaxoSmithKline plc. Prior to that, Ms. Griffin held several finance and strategic planning positions at The Boeing Company. She received a post-graduate certificate in accounting and an MBA from Seattle University and a B.S. in statistics and marketing from George Mason University and has passed the certified public accountant exam.

Peggy Phillips

Ms. Peggy V. Phillips is Independent Director of the Company. Ms. Phillips has been a member of the board of directors of Dynavax Technologies Corp. since 2006. Ms. Phillips served on the board of directors of Tekmira Pharmaceuticals from February 2014 to March 2015. Ms. Phillips served on the board of directors of Portola Pharmaceuticals, a biopharmaceutical company, from 2006 to 2013. From 2003 until 2011, Ms. Phillips served on the board of the Naval Academy Foundation. From 1996 until 2002, she served on the board of directors of Immunex Corporation, a biotechnology company, and, from 1999, she served as the chief operating officer until the company was acquired by Amgen in 2002. During her career at Immunex Corporation, Ms. Phillips held positions of increasing responsibility in research, development, manufacturing, sales and marketing. As Senior Vice President for Pharmaceutical Development and General Manager for Enbrel® from 1994 until 1998, she was responsible for clinical development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining Immunex Corporation, Ms. Phillips worked at Miles Laboratories. The board of directors believes that Ms. Phillips provides significant experience in development and commercialization of biotechnology products. Her background and experience with larger, complex organizations provides significant operational and strategic insights in assessing the strategy of the Company. Ms. Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho.

John Schmidt

Dr. John A. Schmidt, Jr., MD, is Independent Director of the Company. Dr. Schmidt, has served as a member of our board of directors since 2010. From 2008 to 2009, Dr. Schmidt served as the chief scientific officer of Alnylam Pharmaceuticals, Inc., and prior to that, from 2004 to 2008, he was vice president and sole U.S. member of the Sanofi-Aventis U.S. LLC’s Global Discovery Leadership Team where he was responsible for the biotherapeutics, external innovation, and China discovery initiatives. From 2000 to 2004, Dr. Schmidt served as vice president and head of the respiratory and rheumatoid arthritis disease group of legacy Aventis, during which time he advanced more than 15 new chemical entities into preclinical and clinical development. From 1990 to 2000, Dr. Schmidt served as senior director of immunology and rheumatology at Merck Research Laboratories. Dr. Schmidt received a B.S. in biology from St. Joseph’s University in Philadelphia and an M.D. from the University of Pennsylvania.

Erin Cox